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CD24 is overexpressed in glioma cells in vitro and in vivo. However, the correlation of its expression with clinicopathological
parameters of gliomas and its prognostic signiﬁcance in this tumor remain largely unknown. To address this problem, 151 glioma
specimens and 10 nonneoplastic brain tissues were collected. Quantitative real-time PCR, immunochemistry assay, and Western
blot analysis were carried out to investigate the expression of CD24. As per the results, CD24 was overexpressed in gliomas. Its
expression levels in glioma tissues with higher grade (P<0.001) and lower KPS (P<0.001) were signiﬁcantly higher than
those with lower grade and higher KPS, respectively. Cox multifactor analysis showed that CD24 (P = 0.02) was an independent
prognosis factor for human glioma. Our data provides convincing evidence for the ﬁrst time that the overexpression of CD24 at
gene and protein levels is correlated with advanced clinicopathological parameters and poor prognosis in patients with glioma.
1.Introduction
Glioma is the most common type of primary central nervous
system tumor in adults. It is a kind of aggressive tumors with
a tendency to invade the surrounding brain tissue. Despite
thatgreatprogresshasbeenmadeinthesurgical,radioactive,
and chemical antiglioma modalities, the prognosis of this
tumor remains poor. Especially, glioblastoma multiforme
(GBM), the most malignant as well as the most reported
glioma histology, leads to a median life expectancy of only
10–12 months after diagnosis [1]. While the molecular
pathology responsible for the aggressiveness of human
glioma and the suboptimal response to conventional thera-
pies is largely unknown, existing data suggest that a diversity
ofbiologicalchangesingliomacellsmayaccountforthepoor
overall survival of patients with glioma [2]. It is hoped that
a greater understanding of these molecular characteristics
involved in glioma cell proliferation and survival will lead
to new insights into glioma-genic mechanisms and more
eﬀective targeted therapies.
CD24 is a small, heavily glycosylated, mucin-like cell
surface protein that consists of 27 amino acids, and it is
attached to cell membranes by a GPI anchor [3]. It is
expressed in cells of the hematopoietic system, such as B-
cell precursors and neutrophils, in neuronal tissues, and
in certain epithelial cells, such as keratinocytes and renal
tubular epithelial cells [4]. It plays important roles in cell
selection and maturation during hematopoiesis. CD24 has
recently raised attention and lent substantial improvements
for our understanding of tumor biology. Functionally, CD24
enhances the metastatic potential of malignant cells, because
it has been identiﬁed as a ligand of P-selectin, an adhesion
receptor on activated endothelial cells and platelets [5]. Sev-
eralstudieshavereportedthatCD24isbroadlyoverexpressed
on many types of tumor tissues, including erythroleukemia,
B-cell lymphomas, small cell lung cancer, hepatocellular
carcinoma, cholangiocarcinoma, esophageal squamous cell
carcinoma, pancreatic adenocarcinoma, urothelial carci-
noma, prostate carcinoma, ovarian cancer, breast cancer, and
primary neuroendocrine carcinomas [6–10].
In 1999, Senner et al. [11] examined the eﬀect of
CD24 on growth and migration of gliomas in vitro and
in vivo. They found the overexpression of CD24 in human
GBM by immunohistochemical analysis. Their data also
suggested that CD24 stimulated migration of gliomas in
mice. However, the correlation of its expression with2 Journal of Biomedicine and Biotechnology
clinicopathological parameters of gliomas and its prognostic
signiﬁcance in this tumor remain largely unknown. In order
to address this problem, we used quantitative real-time
PCR, immunochemistry assay, and Western blot analysis to
investigate the expression pattern of CD24 in glioma speci-
mens and nonneoplastic brain tissues. Next, we analyzed the
correlationbetweenCD24expressionandthegliomastageas
well as the survival of patients.
2.MaterialsandMethods
2.1. Patients and Tissue Samples. This study was approved
by the Research Ethics Committee of the Institute for func-
tional neurosurgery PLA, TangDu Hospital, Fourth Military
Medical University, China. Written informed consent was
obtainedfromallofthepatients.Allspecimenswerehandled
and made anonymous according to the ethical and legal
standards.
Fresh glioma specimens were obtained from 151 patients
who underwent surgery between February 2003 and March
2006. None of the patients had received radiotherapy or
chemotherapy prior to surgery. Tumors were histopatho-
logically classiﬁed according to the WHO classiﬁcation
[12]. Sixty-eight of the 151 gliomas were classiﬁed as low
grade (31 pilocytic astrocytomas (WHO I) and 37 diﬀuse
astrocytomas (WHO II)), and 83 were classiﬁed as high-
grade gliomas (40 anaplasia astrocytomas (WHO III), and
43 primary glioblastomas (WHO IV)). Patient data included
age, sex, date, and type of initial operation, and details of the
followup. Clinical information was obtained by reviewing
the medical records on radiographic images, by telephone or
written correspondence, and by review of death certiﬁcate.
A patient was considered to have recurrent disease if this
was revealed either by magnetic resonance imaging or
the occurrence of new neurologic symptoms. Parts of the
specimens were ﬁxed in 10% formaldehyde and imbedded
in paraﬃn for histological sections. Other parts were put
into liquid N2 for 10min, then into a −70◦Cu l t r a f r e e z e rf o r
mRNAandproteinisolation.Tennonneoplasticbraintissues
from 10 patients with intractable epilepsy were served as the
control.
For the analysis of survival and followup, the date of
surgery was used to represent the beginning of the followup
period. All the patients who died from diseases other than
glioma or from unexpected events were excluded from the
case collection. Followups were terminated until March
18, 2011. Treatment modalities after relapse were given
according to a uniform guideline.
2.2. Quantitative Real-Time PCR. Quantitative real-time
PCR (QRT-PCR) was performed in a LightCycler (Roche
Diagnostics, Indianapolis, IN) as described previously. PCR
was done with the following primers: CD24 forward primer
5 -TGC TCC TAC CCA CGC AGA TT-3  and reverse primer
5 -GGC CAA CCC AGA GTT GGA A-3 ;a n dβ-actin
(NM 001101): sense, 5 -CTA CAA TGA GCT GCG TGT
GGC-3 ;antisense,5 -CAG GTC CAG ACG CAG GAT GGC-
3 . The region of CD24 do the selected primers amplify is
the coding region of exon 2 (Genbank NM 013230). The
CD24 PCR fragment is 453bp long. The LightCycler analysis
software was used to analyze the PCR data as described
previously [13]. Targets were normalized using β-actin as
internal standard.
2.3. Immunohistochemistry Assay. Immunohistochemistry
was done using avidin-biotin immunoperoxidase technique
as described previously. Brieﬂy, following peroxidase block-
ing with 0.3% H2O2/methanol for 30min, specimens were
blockedwithphosphate-buﬀeredsaline(PBS)containing5%
normal horse serum (Vector Laboratories Inc., Burlingame,
CA, USA). All incubations with a monoclonal antibody
against human CD24 (Ab-2, clone 24C02/SN3b, LAB
VISION, Fremont, CA) at 1:100 dilution were carried out
overnight at 4◦C. Then the specimens were brieﬂy washed in
PBSandincubatedatroomtemperaturewiththeanti-mouse
antibody and avidin-biotin peroxidase (Vector Laboratories
Inc., Burlingame, CA, USA). The specimens were then
washed in PBS and color-developed by diaminobenzidine
solution (Dako Corporation, Carpinteria, CA, USA). After
washing with water, specimens were counterstained with
Meyer’s hematoxylin (Sigma Chemical Co., St Louis, MO,
USA). Nonneoplastic brain tissues were used as control
tissuesandnonimmuneIgGwasalsousedasnegativecontrol
antibody for immunohistochemical staining.
Immunostaining for CD24 protein expression in glioma
and nonneoplastic brain tissues was quantitatively analyzed
with the AxioVision Rel.4.6 computerized image analysis
system assisted with the automatic measurement program
(Carl Zeiss, Oberkochen, Germany). Brieﬂy, to assess the
Mean Optical Density (MOD), which represents the strength
of staining signals by measuring per positive pixels, we
evaluated the stained sections at 200 magniﬁcation and ten
representative staining ﬁelds of each section were analyzed.
T h es c o r e sw e r ee v a l u a t e dt w oi n d e p e n d e n te x p e r i e n c e d
pathologists, who were blinded to the clinicopathologic
parameters and clinical outcomes of the patients. An
immunoreactivity score system was applied as described
previously [14]. The extensional standard was (1) the
number of positively stained cells <5% scored 0; 6–25%
scored 1; 26–50% scored 2; 51–75% scored 3; >75% scored
4; (2) intensity of stain: colorless scored 0; pallide-ﬂavens
scored 1; yellow scored 2; brown scored 3. Multiply (1) and
(2). The staining score was stratiﬁed as-(0 score, absent), +
(1–4 score, weak), ++ (5–8 score, moderate), and +++ (9–
12 score, strong) according to the proportion and intensity
of positively stained cancer cells. Specimens were rescored if
diﬀerence of scores from two pathologists was >3.
2.4. Western Blot Analysis. Glioma and nonneoplastic brain
t i s s u e sw e r eh o m o g e n i z e di nl y s i sb u ﬀer (PBS, 1% Nonidet
P-40 (NP-40), 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), 100μg/mL aprotinin, 100μg/mL
phenylmethylsulfonyl ﬂuoride (PMSF), sodium orthovana-
date) at 4◦C throughout all procedures and sonicated for
70s, then add 300μg PMSF per gram of tissue and incubate
on ice for 30min, followed by centrifugation at 15,000rpm
for 20min at 4◦C. The protein content was determined
according to Bradford’s method (Bradford 1976), withJournal of Biomedicine and Biotechnology 3
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Figure 1: Immunohistochemical staining of CD24 protein in tumor cells of high-grade glioma (a) and nonneoplastic brain (b) tissues
(original magniﬁcation ×400). Staining for this antigen is described in Section 2. Positive staining of CD24 is seen in the cytoplasm and
membrane of tumor cells in gliomas, whereas the nonneoplastic brain tissues showed no expression of CD24.
bovine serum albumin used as a standard. Protein samples
(30μg) were boiled with 2× sample buﬀer containing
5% β-mercaptoethanol for 5min, separated by size on
15% polyacrylamide gel under SDS denaturing conditions,
and transferred to a nitrocellulose membrane at 90V for
2h. The separated proteins were electrotransferred to a
Hybond enhanced chemiluminescence nitrocellulose mem-
brane (Amersham Pharmacia Biotech, Buckinghamshire,
UK). Nonspeciﬁc binding was blocked by incubation in
block buﬀer (5% nonfat dry milk, 0.05% Tween-20, 1× tris-
Cl-buﬀered saline) overnight at 4◦C. The membranes were
hybridized with mouse monoclonal antibody recognizing
CD24 (Ab-1; clone SN3; Neomarkers), then incubated
with a horseradish peroxidase-labeled goat anti-mouse IgG
(1:500). The bound secondary antibody was detected by
enhancedchemiluminescence(AmershamLifeScience,Little
Chalfont, UK). Housekeeping protein β-actin (A5316; clone
AC-74; Sigma) was used as a loading control. Positive
immunoreactive bands were quantiﬁed densitometrically
(Leica Q500IW image analysis system) and expressed as ratio
of CD24 to β-actin in optical density units.
2.5. Statistical Analysis. All computations were carried out
using the software of SPSS version13.0 for Windows (SPSS
Inc, IL, USA). The rank sum test was used to analyze the
ranked data. The measurement data were analyzed by one-
way ANOVA. Randomized block design ANOVA was used to
analyze the statistical diﬀerence among diﬀerent tissue types.
The associations between protein expression and diﬀerent
clinical parameters were evaluated using Fisher’s exact test
or χ2 test. The cumulative survival after tumor removal
was calculated according to Kaplan-Meier, with log-rank
test. Multivariate survival analysis was performed on all the
parameters that were found to be signiﬁcant on univariate
analysis by the Cox proportional hazard regression model.
Diﬀerences were considered statistically signiﬁcant when P
was less than 0.05.
3. Results
3.1. Immunohistochemical Expression of CD24 Protein in
Glioma Tissues and Its Correlation with Survival of Patients.
CD24 expression was studied in a total of 151 glioma speci-
mens of which 68 were low grade glioma (grade I and II) and
83 were high grade (grade III and IV). About 10 specimens
taken from nonneoplastic brain tissues served as control
group. Based on the immunohistochemistry analysis, CD24
wasexpressedinthecytoplasmandmembraneoftumorcells
in gliomas (Figure 1(a)), whereas the nonneoplastic brain
tissues showed no expression of CD24 (Figure 1(b)). Among
the glioma specimens, 110 (72.8%) glioma specimens were
positively stained, and 41 (27.2%) glioma specimens were
negatively stained. We also found a signiﬁcant diﬀerence of
CD24 expression between glioma and nonneoplastic brain
tissues (P<0.001).
Table 1 summarizes the association of CD24 immunos-
taining with the clinicopathological parameters of the
gliomas. CD24 expression was not signiﬁcantly aﬀected by
the gender and age (both P>0.05) of the patients. In
contrast, CD24 expression was the closely correlated with
WHO grade, as well as Karnofsky performance Status (KPS).
The positive expression rates of CD24 in glioma tissues with
grades III∼IV and KPS < 80 were signiﬁcantly higher than
those with grades I∼II (Table 1; P<0.01) and KPS ≥ 80
(Table 1; P<0.01), respectively.
We reviewed clinical information of these CD24-positive
or -negative glioma patients. During the follow-up period,
118 of the 151 glioma patients (78.1%) had died (23
from the CD24-negative group and 95 from the CD24-
positive group). In univariate survival analysis, we used the
Kaplan-Meier method to calculate the cumulative survival
curve and the diﬀerences in survival were accessed by the
log-rank method. The conventional prognostic parameters
including WHO grade and KPS reached signiﬁcance for the
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Figure 2: Postoperative survival curves for patterns of patients with glioma and CD24 expression. (a) Kaplan-Meier postoperative survival
curve for patterns of patients with glioma and CD24 expression. Unadjusted RR of CD24-negative and -positive groups were 1.0 and 0.02,
respectively (P = 0.01). (b) Cox proportional hazards model after adjusting for age, gender, and grade. CD24 might be an independent
predictor of survival, without consideration of age, gender, or grade. Adjusted RR of CD24-negative and positive groups were 1.0 and 0.04,
respectively (P = 0.02).
Table 1: CD24 expression in human glioma tissues with diﬀerent
clinical-pathological features.
Clinicopathological





I3 1 1 6 1 5
<0.01 II 37 12 25
III 40 8 32
IV 43 5 38
Age
<55 81 20 61 NS
≥55 70 21 49
Gender
Male 78 25 53 NS
Female 73 16 57
KPS
≥80 66 31 35 <0.01
<80 85 10 75
a signiﬁcant shorter survival than those with CD24-negative
tumors (P = 0.01; Figure 2(a)). The median survival times
of patients with positive and negative expression of CD24
were 13.6±2.0 months and 22.8±1.3 months (log rank test:
P = 0.01).
Table 2: Statistics of CD24 mRNA levels in glioma.
No. of cases CD24 mean (SD) P
Tissue type
Control 10 0.065 (0.087) <0.001
Glioma 151 2.386 (0.230)
WHO grade
I 31 0.873 (0.101)
<0.001 II 37 1.552 (0.113)
III 40 3.021 (0.220)
IV 43 3.604 (0.378)
KPS
≥80 66 1.328 (0.162) <0.001
<80 85 3.208 (0.331)
Figure 2(b) shows the cumulative survival curve of
patients with glioma and CD24 expression after adjusting for
age, gender, WHO grade, and KPS. By multivariate analysis,
the overexpression of CD24 (P = 0.02) was a signiﬁcant and
independent prognostic indicator for patients with glioma
besides age, WHO grade, and KPS. The Cox proportional
hazards model showed that higher CD24 expression was
associated with poor overall survival.
3.2. Western Blot Analysis of CD24 Protein Expression in



















































Figure 3: Expression of CD24 protein in glioma and nonneoplastic
brain tissues by Western blot analysis. (a) CD24 expression levels in
glioma and nonneoplastic brain tissues. (b) CD24 expression levels
in glioma with diﬀerent WHO grades. (c) CD24 expression levels in
nonneoplastic brain tissues and glioma with diﬀerent WHO grades.
“N” refers to nonneoplastic brain tissues; “Ca” refers to glioma
tissues; “Ca I” ∼ “Ca IV” refer to glioma tissues with WHO grade
I∼IV. β-actin was used as a control for equal protein loading. Values
are means ± SD. “∗”, P<0.05, comparison with nonneoplastic
brain tissues; “∗∗”, P<0.01, comparison with nonneoplastic brain
tissues.
the results of quantitative analysis of CD24 protein expres-
sion levels detected by Western blot. We found that CD24
proteinexpressiontendedtoincreasefromthenonneoplastic
braintissuestothegliomatissues(Figures3(a)and3(c)).We
also investigated whether the expression of CD24 correlated
with the WHO grade. CD24 expression was lowest in grade
I and highest in grade IV (Figures 3(b) and 3(c)). This
result agreed with the ﬁndings of the immunohistochemistry
analysis and indicated a close correlation of CD24 protein
expression with WHO grade.
3.3. Quantitative Real-Time PCR Analysis of CD24 Gene
Expression in Gliomas. Table 2 summarized the results of
quantitative real-time PCR analysis of CD24 gene expression
in gliomas with various clinicopathological features. There
wasaconspicuousincreaseintheexpressionofCD24mRNA
from the control nonneoplastic brain tissues to glioma
tissues (P<0.001). We further analyzed the expression of
CD24 mRNA based on KPS and WHO grade. Interestingly,
CD24 mRNA expression increased in the patients whose
K P Sl o w e rt h a n8 0( P<0.001) and also increased with
advancement of WHO grades I to IV (P<0.001).
4. Discussion
In the present study, we examined the expression of CD24
in 151 cases of human glioma and compared its expression
with tumor grade and survival rates of patients. Our
data demonstrated that CD24 protein was overexpressed
in gliomas compared to nonneoplastic brain tissues. CD24
mRNA expression in glioma tissues was also signiﬁcantly
higher than that in the nonneoplastic brain tissues. In
addition, an increased trend of both CD24 protein level
and mRNA level from WHO grade I to WHO grade IV
glioma has been found. These results suggest that the
transcriptional repression of human CD24 might participate
in the carcinogenesis and progression of glioma. CD24 may
have an important role during the genesis or progression
of glioma. Moreover, the expression of CD24 in gliomas
was a novel prognostic factor in gliomas that retained its
prognostic impact on overall survival even in a multivariate
analysis. To our best knowledge, this is the ﬁrst study on the
clinical and prognostic signiﬁcance of CD24 expression in
human gliomas.
CD24, ﬁrst identiﬁed in 1978 when Springer produced
xenogenic rat antimouse antibodies M1/69 and M1/75, was
called as heat stable antigen due to its heat resistance [15]. In
1990, the human CD24 gene was identiﬁed. Human CD24
is located on chromosome 6q21, as determined by in situ
hybridization [16]. The primary structure of human CD24
shows multiple N- or O-glycosylation sites. The human
CD24 molecule has additional serine and threonine residues,
rendering the molecule like a mucin. CD24 protein isolated
from diﬀerent tissues or cell types has diﬀerent molecular
weights, ranging from 20 to 70kd, demonstrating that the
glycosylation of heat-stable antigen and CD24 is highly
variable and cell-type dependent [17]. It has been identiﬁed
as a ligand for P-selectin and the cell adhesion molecule L1-
CAM. CD24 is able to support the adhesion of neutrophils
or monocytes to activated endothelial cells or thrombin-
activated platelets, both of which express P-selectin. CD24-
expressing tumor cells can disseminate more readily through
their capacities to form thrombi with activated platelets
or adhere to endothelial cells in the bloodstream. The
interaction of tumor cells with P-selectin via CD24 may be
an important adhesion pathway in cancer metastasis [18,
19]. Furthermore, CD24 expression indirectly stimulates cell
adhesion to ﬁbronectin, collagen I, collagen IV, and laminin
throughactivationofa3b1anda4b1integrinactivities.CD24
is regulated by Ral GTPases, suggesting that CD24 and other
potentialtranscriptionaltargetsofRalsignalingmaymediate
important functional aspects of the members of this GTPase
subfamily that are emerging as central players in cancer
[20, 21].
Accumulating evidence indicates that CD24 is an impor-
tant marker for cancer diagnosis and prognosis. For various
metastatic tumors, most studies have reported that the
overexpression of CD24 protein might contribute to metas-
tasis and by consequence poor prognosis. In non-small-cell
lung cancer, CD24 expression is an independent marker
for the overall survival of cancer patients [22]. In breast
cancer, CD24 expression is signiﬁcantly higher in invasive6 Journal of Biomedicine and Biotechnology
carcinoma than in precancerous lesions. Cell-surface and
cytoplasmicexpressionofCD24correlatestopoorprognosis,
histology grades, tumor sizes, and lymph node positivity
[23]. In addition, CD24 is a marker of shorter survival
for patients with intrahepatic cholangiocarcinoma [24].
Overexpression of CD24 in hepatocellular carcinoma was
associated with high invasiveness and metastatic potential,
hightumorproliferationstatus,andactivationoftheWnt/β-
catenin pathway. CD24 may be a novel predictor for poor
prognosis of HCC patients after surgery [25]. Moreover,
in esophageal squamous cell carcinoma, CD24 expression
correlates with tumor lymph node metastasis, tumor grade,
and survival time [8]. Similar observations were found
in many types of cancer, including ductal carcinoma of
the pancreas, cholangiocarcinoma, urothelial carcinoma,
ovarian cancer, and prostate cancer [7–10]. Furthermore, it
has been demonstrated that small-interfering RNA silencing
of CD24 expression in tumor cell had a direct eﬀect on
tumor cell proliferation and survival in tissue culture. For
example, Overdevest et al. manipulated CD24 expression
in human bladder cancer cell lines using shRNA depletion,
cDNA overexpression, and FACS selection. CD24 was found
necessary for subsequent development of lung metastases.
They next treated clinically detectable lung metastases in
mice with anti-CD24 antibody and observed reduced tumor
growth and prolonged survival. These ﬁndings suggest
that CD24 is a lynchpin of metastatic progression and
a promising therapeutic target for antimetastatic therapy
[4]. Similar observations were found by Sagiv and Arber,
who demonstrated that the anti-CD24 monoclonal antibody
can inhibit the growth of human pancreatic cell lines in
vitro by the antibody-blocking experiments. Importantly,
targeted mutation of CD24 signiﬁcantly reduced the size
of hepatocellular carcinomas induced by the transgenic
expression of hepatitis virus B genes [26].
For human glioma, an essentially nonmetastatic tumor,
CD24 might promote the tumor invasion which leads to
poor prognosis of patients. CD24 has been reported to be
involved in B-cell development and neoplasia, in the devel-
oping brain. Using reverse transcriptase polymerase chain
reaction on 13 pineal parenchymal tumors, F` evre-Montange
et al. in 2003 demonstrated that CD24 might be one of
candidates for grading pineal parenchymal tumors with
intermediate diﬀerentiation [27]. Senner et al. found the
immunohistochemical overexpression of CD24 in human
GBM cells and it also promotes invasion of glioma cells
in vivo [11]. Lo et al. [28] further showed that one of the
GLI1 upregulated genes, CD24, an invasion-associated gene
to be required for the migratory and invasive phenotype
of GBM cells. Consistent with these previous reports, our
group also conﬁrmed that CD24 expression in gene and
protein levels was both increased from nonneoplastic brain
tissues to glioma tissues. Its expression levels increase from
grades I to IV glioma on quantitative real-time PCR,
immunohistochemistry analysis, and Western blot analysis.
We further analyzed the correlation of CD24 expression
and survival rates of patients. Our data indicated that the
survival rate of patients with CD24 staining was lower than
thosewithoutit. Kaplan-Meieranalysisofthesurvivalcurves
showed a signiﬁcantly worse overall survival for patients
whose tumors had positive CD24 expression, indicating that
positive CD24 expression is a marker of poor prognosis for
patientswithglioma.Moreover,multivariateanalysisshowed
positive CD24 expression to be a marker of worse outcome
independentoftheknownclinicalprognosticindicatorssuch
as age, KPS, and grade. These data suggest that positive
expression of CD24 is correlated with a worse outcome of
patients with glioma. Thus, CD24 might be an independent
predictor of survival for glioma patients.
In conclusion, our data provides convincing evidence for
the ﬁrst time that the overexpression of CD24 at gene and
p r o t e i nl e v e l si sc o r r e l a t e dw i t hp o o ro u t c o m ei np a t i e n t s
with glioma. CD24 expression may be a novel prognostic
marker for human glioma.
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